Fortress Rapid Antigen Test

Rapid antigen testing for COVID-19

Rapid results in 15 minutes

Excellent performance

Manufactured in the UK

CE Marked

The Fortress Covid-19 Antigen Test is a single-use in vitro immunochromatographic assay for the qualitative detection of nucleocapsid protein antigen from 2019 novel coronavirus (SARS-CoV-2) in nasopharyngeal swab specimens, directly from patients suspected for infection with SARS-CoV-2 by their healthcare provider.

In the ongoing battle against COVID-19, accessible near patient diagnostic testing is a powerful tool to help screening. As more and more people seek to return to the ‘new normal’ antibody and antigen tests will be invaluable to the success of helping schools and universities remain open, businesses returning to the office, health workers avoiding quarantine, increased protection in our care homes and future airport control.

We are now offering the Fortress Diagnostics Ag-Rapid Test. It offers quicker results for more efficient and effective treatment of Sars-CoV-2. Antigens are generally detectable in upper respiratory specimens during the acute phase of infection. Rapid diagnosis of SARS-CoV-2 infection will help healthcare professionals to treat patients and control the disease more efficiently and effectively.


The Fortress Diagnostics Rapid Antigen Test…

> Rapid testing for SARS-CoV-2 antigen within 15 minutes

> Nasopharyngeal swab sample

> Facilitates patient treatment decisions quickly

> Simple, time-saving procedure

> All necessary reagents provided & no equipment needed

> High sensitivity and specificity

> Room temperature storage

Contact us to find out more

Downloads and resources

Fortress Rapid Antigen Test Sales Sheet
Fortress Rapid Antigen Test IFU

Contact our team

What we do with your data

NG Biotech CARBA 5
Because there's more to public health than COVID-19...

"We love the ease and accuracy of the NG CARBA-5 lateral flow test. It has decreased our turnaround times and means we no longer need the reference laboratory to confirm our presumptive CPO results." - Holly Ciesielczuk, Senior Clinical Scientist at Barts Health NHS Trust

Read More